SOURCE: Kalorama Information

Kalorama Information

June 17, 2010 10:34 ET

New Products Could Add Over $70 Billion to the Pharmaceutical Market in Five Years

NEW YORK, NY--(Marketwire - June 17, 2010) -  The pharmaceutical market may soon see the result of an increase in research and development at Big Pharma over the past few years, according to healthcare market research publisher Kalorama Information. The top fifty pharmaceutical companies in the world have some 550 projects in late stage development, and Kalorama Information estimates that these projects have the potential to add a value of more than $70 billion in additional revenues to the pharmaceutical market by 2015. This is according to Kalorama Information's new market research report "World Pharmaceutical and Biopharmaceutical Market, 2010-2015 (Pipeline Analysis of the Top 50 Companies)."

"There's a wave of new products coming and we think enough of them will reach commercialization so that, on top of the organic growth we might normally expect in the market, this will add additional value," said Melissa Elder, analyst for Kalorama Information. "This is good news for an industry hit with a shortage of new products, an economic recession and new taxes."

According to the report, drugs in the oncology segment are expected to make a significant impact on current markets, increasing competition and providing advanced alternatives to current therapies. There are over 140 cancer drugs in development and these alone could possibly make up nearly a third of the potential value that will be added to the pharmaceutical market. This is followed by development projects in the areas of cardiovascular and blood, neurotherapeutics, respiratory and inflammation, infectious diseases, gastrointestinal drugs, and other drugs.

Biopharmaceutical projects dominate these late-stage efforts, and should provide the bulk of the growth in revenue. The report indicates that traditional pharmaceutical companies such as Pfizer, Merck and Novartis have joined the biopharmaceutical industry lead by Amgen and Gilead Sciences, and their pipelines include a number of monoclonal antibody products for diseases such as renal, gastric and breast cancer. The line between what is a pharmaceutical company and what is a biopharmaceutical company is becoming blurred, according to the report. Many large firms told Kalorama Information they consider themselves both pharmaceutical and biopharmaceutical companies. 

These and many more topics, as well as a complete review of the late-stage projects of 50 companies, are presented in "World Pharmaceutical and Biopharmaceutical Market, 2010-2015 (Pipeline Analysis of the Top 50 Companies)," which can be obtained at Kalorama Information at

About Kalorama Information
Kalorama Information supplies the latest in independent market research in the life sciences, as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on Twitter ( and LinkedIn (

Contact Information